Singapore-Based injewelme Raises $1.2 Million in Seed Funding
Injewelme, a Singaporean healthtech startup that leverages data technology to enhance health monitoring, has successfully raised $1.2 million in a seed funding round. The funding, announced on April 8, 2026, was led by Catalytic Capital for Climate and Health (C3H), a strategic investment vehicle associated with Temasek Trust.
Company and Leadership
Founded by James Moon, who also serves as CEO, injewelme aims to transform preventive healthcare through advanced AI technologies. The company focuses on data-driven health monitoring solutions that provide continuous insights into various health parameters.
Use of Funds
The newly secured funds will be directed towards the further development of injewelme’s DeepHealthVision (DHV) platform. This technology utilizes remote photoplethysmography (rPPG) to enable contactless monitoring of over 20 vital health indicators, such as heart rate, blood pressure, and oxygen saturation. The DHV system boasts an impressive 95% detection accuracy in pilot programs.
Injewelme plans to expand the capabilities of DHV to include additional health metrics like blood glucose levels, stress, fatigue, and hydration. The funding will also support the company's expansion efforts within Singapore and across other Southeast Asian markets, enhancing its ability to monitor the effects of climate-related stress.
Strategic Plans
The investment will allow injewelme to broaden the application of its technology across various industries, potentially reaching a wider audience in Southeast Asia. By advancing its AI-driven health monitoring solutions, the company aims to position itself as a leading player in the preventive healthcare sector.
In summary, this funding round marks a significant step for injewelme as it continues to innovate in the field of health monitoring technology, driven by data and AI. With the backing of C3H, the company is poised to make a substantial impact on health outcomes in the region.